Current Perspectives on Neonatal Screening for Propionic Acidemia in Japan: An Unexpectedly High Incidence of Patients with Mild Disease Caused by a Common PCCB Variant.
Go TajimaReiko KagawaFumiaki SakuraAkari Nakamura-UtsunomiyaKeiichi HaraMiori YuasaYuki HasegawaHideo SasaiSatoshi OkadaPublished in: International journal of neonatal screening (2021)
Propionic acidemia (PA) is a disorder of organic acid metabolism which typically presents with acute encephalopathy-like symptoms associated with metabolic acidosis and hyperammonemia during the neonatal period. The estimated incidence of symptomatic PA in Japan is 1/400,000. The introduction of neonatal screening using tandem mass spectrometry has revealed a far higher disease frequency of approximately 1/45,000 live births due to a prevalent variant of c.1304T>C (p.Y435C) in PCCB, which codes β-subunit of propionyl-CoA carboxylase. Our questionnaire-based follow-up study reveals that most of these patients remain asymptomatic. However, reports on symptomatic patients exhibiting cardiac complications such as cardiomyopathy and QT prolongation have been increasing. Moreover, there were even cases in which these cardiac complications were the only symptoms related to PA. A currently ongoing study is investigating the risk of cardiac complications in patients with neonatal screening-detected PA caused by this common variant.
Keyphrases
- end stage renal disease
- risk factors
- ejection fraction
- newly diagnosed
- tandem mass spectrometry
- chronic kidney disease
- left ventricular
- heart failure
- prognostic factors
- peritoneal dialysis
- drug induced
- emergency department
- high resolution
- patient reported outcomes
- simultaneous determination
- liver failure
- cross sectional
- patient reported
- hepatitis b virus
- single cell
- ms ms
- fatty acid
- extracorporeal membrane oxygenation